Business · 03/02/2003Updated: 10/17/2026 · 1 min read
FDA Releases Draft Guidance for Labeling Noncontraceptive Estrogen Drug Products
Summary
The Food and Drug Administration (FDA) has made available a draft guidance document to help healthcare providers and patients understand the labeling requirements for noncontraceptive estrogen drug products used to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →